AlphaMadera's AlphaVal page computes Victoria's Secret & Company's fair value using a multi-method blend (DCF, comparable-multiples, and Graham-style intrinsic value), then compares it to the current market price to flag VSXY as undervalued, fairly valued, or overvalued.

What is Victoria's Secret & Company's fair value?

Fair value for VSXY is a model output combining discounted cash flow projections, peer-group multiples, and a Graham number floor. The live AlphaVal page shows the blended fair value alongside each method's individual estimate.

How does AlphaMadera value VSXY?

AlphaVal uses three primary techniques: a five-year discounted-cash-flow projection with terminal multiple, peer-group multiple analysis (P/E, EV/EBITDA, P/S), and Graham's defensive-investor intrinsic-value formula. Inputs come from VSXY's most recent reported fundamentals.

VSXY - Victoria's Secret & Company

Price: -- -- | CONSENSUS: Buy DETAILS | PRICE TARGET: $88.00 DETAILS

AlphaVal

Deterministic, archetype-aware fair value

Stable Earnings Power 80% confidence

Primary model: P/Adj-EPS × Normalized Multiple

Valuation Signal Overvalued Strong

Trading 80.4% above fair value

Current Price $82.79

Bear Case $40.17 51.5% downside ($40.17 - $82.79) / $82.79 = -51.5% $2.21 × 14x P/E

Fair Value $45.90 44.6% downside ($45.90 - $82.79) / $82.79 = -44.6% $2.21 × 16x P/E

Bull Case $51.64 37.6% downside ($51.64 - $82.79) / $82.79 = -37.6% $2.21 × 18x P/E

Adjust Assumptions

P/E Multiple

16.0x

Adjusted EPS

2.21$

Key Value Driver

Normalized P/E multiple (16x base case)

Implied Market Multiple 37.4x

Plain-Language Summary

Our base-case estimate uses a valuation based on adjusted earnings per share and a normalized price-to-earnings multiple. We then blend that result with the average analyst price target of $88.00 from 9 analysts, using a 20% weight on analyst consensus. That produces an estimated intrinsic value of $45.90 per share.

Warnings

ℹ Wall Street's average price target is $88.00 (from 9 analysts). Our estimate is 60% below the consensus -- consider that gap carefully.

Key Risks

Growth DCF inappropriate — terminal value assumptions dominate
EV/EBITDA misleading for regulated businesses where capex is mandated
Regulatory risk is a fat tail not visible in normal multiples